治疗|阿贝西利多少钱一盒？阿贝西利治疗乳腺癌效果怎样？( 三 ) 阿贝西利|内分泌|中国|Centre|患

[13] Finn RS, Martin M, Rugo HS, et al. Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med. 2016 Nov 17;375(20):1925-1936.
[14] Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016 Apr;17(4):425-439.
[15] Goetz MP, Toi M, Campone M, et al. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. J Clin Oncol. 2017 Nov 10;35(32):3638-3646.
[16] Goetz MP, O'Shaughnessy J, Sledge GW, et al. The benefit of abemaciclib in prognostic subgroups: An exploratory analysis of combined data from the MONARCH 2 and 3 studies. 2017 SABCS. GS6-02.
[17] Leo AD, Dickler M, Sledge GW, et al. Efficacy and safety of abemaciclib in patients with liver metastases in the MONARCH 1, 2, and 3 studies. 2017 SABCS. P5-21-02.
[18] Sahebjam S, Rhun EL, Kulanthaivel P, et al. Assessment of Concentrations of Abemaciclib and its Major Active Metabolites in Plasma, CSF, and Brain Tumor Tissue in Patients With Brain Metastases Secondary to Hormone Receptor Positive (HR+) Breast Cancer. Journal of Clinical Oncology 34, no. 15_suppl (May 20, 2016) 526-526. [19] Anders CK, Rhun EL, Bachelot TD, et al. A phase II study of abemaciclib in patients (pts) with brain metastases (BM) secondary to HR+, HER2- metastatic breast cancer (MBC). Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019) 1017-1017.
[20] Li J, Jiang J, Wu J, et al. Physiologically Based Pharmacokinetic Modeling of Central Nervous System Pharmacokinetics of CDK4/6 Inhibitors to Guide Selection of Drug and Dosing Regimen for Brain Cancer Treatment. Clin Pharmacol Ther. 2021 Feb;109(2):494-506.
[21] Harbeck N, Johnston S, Fasching P, et al. High Ki-67 as a biomarker for identifying patients with high risk early breast cancer treated in monarchE. 2020 SABCS. PD2-01.
[22] André F, Ciruelos E, Rubovszky G, et al. SOLAR-1 Study Group. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2019 May 16;380(20):1929-1940.
[23] Rugo HS, Bianchi GV, Chia Stephen K. L, et al. BYLieve: A phase II study of alpelisib (ALP) with fulvestrant (FUL) or letrozole (LET) for treatment of PIK3CA mutant, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (aBC) progressing on/after cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy. Journal of Clinical Oncology 36, no. 15_suppl.